Abstract Work over the last decade has revealed novel regulatory mechanisms in pathological disease states that are mediated by microRNAs and has inspired researchers to begin elucidating the specific roles of miRNAs in the regulation of genes involved in cancer development and progression. Recently, miRNAs have been explored as therapeutic targets and diagnostic markers of cancer. In this paper, we review recent advances in the study of miRNAs involved in tumorigenesis, focusing on miRNA regulation of genes that have been demonstrated to play critical roles in lung cancer development. We discuss miRNA regulation of genes that play critical roles in the process of malignant transformation, angiogenesis and tumor metastasis, the dysregulation of miRNA expression in cancer development, and the development of miRNA-based diagnostics and therapeutics.
1 Introduction miRNAs are a class of short, 19-to 25-nucleotide-long RNAs that regulate gene expression by binding to sequences in the 3′ untranslated region (3′UTR) of an expressed mRNA, resulting in either modulation of translation efficiency or degradation of the mRNA [1] [2] [3] . To date, there are ∼700 annotated human miRNA loci that form short stem-loop structures when transcribed and produce either one or two mature miRNAs. Mature miRNAs are typically only partially complementary to their target mRNAs, meaning that each miRNA can regulate a broad set of targets. miRNAs have been shown to regulate expression of a variety of genes involved in cell proliferation, differentiation, apoptosis, stem cell development, and human disease. Recent studies have demonstrated the critical role of miRNAs in cancer pathogenesis [4] [5] [6] [7] [8] [9] [10] . The potential of restoring levels of aberrantly underexpressed miRNAs with miRNA mimics or inactivating over-expressed miRNAs with miRNA inhibitors has been explored and shows promise as the next generation of therapeutic strategies [11] [12] [13] [14] [15] . More recently, miRNAs have been detected in peripheral blood [16] [17] [18] [19] , which also makes them attractive candidates as biomarkers for noninvasive and early cancer detection.
Conventional wisdom in the field of oncology suggests that the development and progression of malignant neoplasias involve multiple genetic changes, each of which can result in the dysregulation of crucial pathways involved in cellular processes such as growth, proliferation, and survival. The accumulation of these genetic alterations confers a malignant phenotype that can be described by six primary hallmarks of cancer: unlimited cell proliferation, autonomous growth without the need for external signals, resistance to growth inhibitory signals, escape from apoptosis (programmed cell death), the ability to recruit new vasculature (neo-angiogenesis), and increased tissue invasion and metastasis [20] . Over the past 30 years, many genes have been implicated in malignant transformation, with altered expression or function contributing to one or more of the hallmarks. Although the roles of many genes in tumorigenesis have been clearly defined, the mechanisms by which they are altered in cancer development are not completely understood. Recent work has revealed a complex layer of regulation mediated by microRNAs. Although we are far from full elucidation of these regulatory relationships, important clues have already emerged that implicate the altered expression of these enigmatic molecules as critical to the process of tumorigenesis.
miRNA regulation of the intracellular processes controlling cancer cell survival and growth
Four of the six major hallmarks-unlimited cell proliferation, autonomous growth, resistance to growth inhibitory signals, and escape from apoptosis-are central to the transformation of a normal cell to a cancer phenotype, the initial step of tumorigenesis. Many genes have been demonstrated to affect one or more of these four ratelimiting processes. Normal cell growth is tightly controlled to maintain homeostasis through a finely tuned balance of mitogenic and anti-proliferative signal cascades. The concerted action of critical cell cycle molecules such as RAS, the cell cycle regulator phosphatase and tensin homolog (PTEN), MYC, and Abl normally keeps cellular proliferation under control; altered expression of key regulators can disrupt this balance and promote deregulated growth. Programmed cell death (apoptosis) is a critical cellular process that normally serves to maintain cell proliferative homeostasis and prevent the unrestricted division of cells [21] . Disruption of apoptotic processes can allow genetically unstable cells to bypass programmed cell death, thereby allowing them to accumulate further mutations that can result in tumorigenesis. miRNAs have recently been implicated as important modulators of these cell growth and survival processes, and their dysregulation can initiate malignant transformation and unchecked cellular growth.
miRNA regulation of growth factor receptors
Altered expression of cell surface growth factor receptors such as receptor tyrosine kinases (RTKs) is the major mechanism that leads to the self-sufficient growth of cancer cells and is a primary phenotypic characteristic of many malignancies, including lung cancers, a paradigm that has served as the basis for the development of targeted cancer therapies. Members of the ErbB family of RTKs, such as the epidermal growth factor receptor (EGFR/ErbB1), ErbB2 (HER2/Neu), ErbB3 and ErbB4, can initiate signal cascades leading to DNA synthesis and cell proliferation, and over-expression of these receptors is often critically involved in tumorigenesis and cancer cell proliferation [22] .
Rapidly accumulating evidence suggests that miRNAs could be critically involved in the regulation of RTKs in certain tumor types. For example, ErbB2 and ErbB3 are implicated in cell proliferation in breast cancers that overexpress these proteins, and the expression of miR-125a and miR-125b has been shown to down-regulate the expression and activity of these receptors in a breast cancer cell line [23] . EGFR has shown marked over-expression in several tumor types, including lung cancer, and has been the focus of several targeted agents designed to suppress its activity in lung cancer and other malignancies. Recent investigations have demonstrated that miRNAs are likely to be involved in the regulation of EGFR in lung cancer. An inhibitor of miR-128b resulted in up-regulated EGFR expression in an EGFR-expressing NSCLC cell line, and treatment with a miR-128b mimic resulted in a concomitant reduction of EGFR expression [24] . Furthermore, clinical analysis of 58 patients with NSCLC who were treated with gefitinib, a small-molecule tyrosine kinase inhibitor against EGFR, showed that loss of miR-128b was significantly associated with improved disease control following treatment (p = 0.03) and improved survival (23.4 versus 10.5 months, p=0.02) [24] . The let-7 miRNA was also shown to reduce EGFR mRNA and protein expression in several cancer cell lines, including those derived from lung, suggesting a role in the regulation of cellular processes involved in lung cancer initiation and progression [25] .
The above and other studies [26, 27] clearly indicate that miRNA regulation can contribute to the aberrant expression of growth factor receptors leading to the uncontrolled growth of tumor cells. However, the significance of some of these regulations, such as regulation of PDGF by miR-140 [26] in lung cancer development, has not yet been evaluated.
miRNA regulation of proto-oncogenes RAS and MYC
The proto-oncogene RAS is the central molecule of the SOS-RAS-Raf-MAPK cascade which is the downstream cytoplasmic effector of the growth factor receptors. Approximately 20% of tumors in general and 30% of lung tumors have activating mutations in one of the RAS genes [28] . These mutations can contribute to several aspects of the malignant phenotype, including dysregulated cell growth [29] . One of the downstream effectors of the RAS signaling pathway is the MYC oncogene. MYC amplification and over-expression have been detected in different histologic subtypes of lung cancer [30] . Both RAS and MYC are targets of the let-7/miR-98 family of miRNAs. Johnson et al. [31] showed that members of the let-7 family of miRNAs bind to the 3′UTR of RAS, down-regulating RAS expression in human cells, that let-7 is poorly expressed in lung cancer compared to normal lung tissue, and that the expression of let-7 is inversely correlated with the expression of RAS in lung tumor samples. Kumar et al. [32] showed that over-expression of let-7 inhibited the growth of k-RAS expressing lung cancer cells in vitro, inducing cell cycle arrest and cell death, and that induced over-expression of let-7g resulted in significant reduction of tumor growth in a lung cancer xenograft model. In another study, let-7a was independently shown to down-regulate MYC and reverted MYC-induced growth in Burkitt lymphoma cells [33, 34] . Together, these data suggest that over-expression of RAS and MYC due to let-7 downregulation could be a primary mediator of tumor cell proliferation and that let-7 family members could be important markers of tumorigenic processes.
miRNA regulation of replicative potential
Maintenance of telomeric DNA is one of the mechanisms leading to unlimited replicative potential. The ability of cancer cells to replicate indefinitely (immortalization) is related to their ability to maintain telomere length, either through the down-regulation of telomerase, by lengthening telomeres through the activity of human telomere reverse transcriptase (hTERT), or through alternative lengthening of telomeres which occurs through the process of recombination-mediated elongation [35] . Several miRNAs have been implicated in the regulation of genes involved in maintaining telomere length. A non-significant inverse correlation between hTERT and miR-138 expression was observed in thyroid cancer cell lines, with miR-138 downregulated in tumor cells relative to normal tissues [36] . DNA methyltransferases (DNMTs) have been recently shown to play critical roles in controlling telomere length [37] . Deficiency in Dicer1, the cytoplasmic ribonuclease that processes precursor miRNAs into short doublestranded RNAs, leads to decreased expression of DNA methyltransferases and increased telomere elongation in a retinoblastoma-like 2 protein (Rbl-2)-dependent manner, with Rbl-2specifically targeted and down-regulated by members of the miR-290 family [38] . In lung cancer cell lines, forced expression of members of the miR-29 family decreases the expression of DNMT3A and -3B, two DNMTs that have been shown to control telomere length and recombination in mammalian cells, and restores normal methylation patterns [39] . An inverse correlation between expression of miR-29s and that of DNMT3A and -3B was also observed in lung cancer tissues.
Although the significance of miRNA regulation of telomere length has not been fully evaluated in in vivo studies, the current data suggest that miRNAs could affect telomere homeostasis and elongation and that the altered expression of miRNAs regulating this pathway could potentially contribute to the unlimited replicative potential of cancer cells.
miRNA regulation of apoptotic pathways
Defects in apoptosis occur in over half of malignant tumors, predominantly due to up-regulation of the anti-apoptotic Bcl-2 proteins or to mutations in the p53 tumor suppressor [40] . The miR-15/miR-16 cluster of miRNAs has been shown to negatively regulate the expression of Bcl-2 at the posttranscriptional level, with this cluster of regulatory elements frequently deleted or otherwise down-regulated in a variety of tumor types [41] [42] [43] . Up-regulation of Bcl-2 protein through decreased expression of these miRNAs could therefore be a major determinant of malignant transformation and exogenous administration of these regulatory elements could provide a therapeutic benefit in miR-15/16-deficient cancers. A study in cholangiocarcinoma cells showed that miR-29 directly targets and downregulates the expression of Mcl-1 protein [44] , a member of the Bcl-2 family that has been found to be over-expressed in a number of human cancers. miR-29 is down-regulated in a number of human cancers including lung cancers, and its ability to repress Mcl-1 coupled with its role in regulating epigenetic DNA methylation [39] means that enhancing expression of this regulatory element could be an effective therapeutic strategy [16, 45, 46] . miR-21 is an anti-apoptotic miRNA that was first identified as an antagonist of programmed cell death in glioblastoma cells. miR-21 levels were shown to be elevated in glioblastoma tissues, with knockdown of miR-21 resulting in caspase activation and apoptosis in vitro [47] . Oligonucleotide inhibitors of miR-21 were also shown to increase apoptosis in a breast cancer xenograft model, an effect that was likely due to down-regulation of Bcl-2 [15] . Inhibition of miR-21 was recently shown to enhance the anti-apoptotic potential of an anti-EGFR tyrosine kinase inhibitor in an EGFR-mutant lung adenocarcinoma cell line [48] .
Members of the miR-34 family of miRNAs are underexpressed in a variety of tumors [4] and have been implicated in the regulation of apoptosis depending on the context in which they are expressed. In lung cancer cells, induction of miR-34 results in apoptosis [49, 50] and miRNA profiling shows that the expression of miR-34a, miR-34b, and miR34c are directly correlated with expression of the p53 tumor suppressor [51] , suggesting that miR-34 is involved in regulating apoptosis as a regulatory target of p53. In osteosarcoma cells, over-expression of this same miRNA resulted in apoptosis and G1 cell cycle arrest [49, 50] .
Since apoptosis is a complex process that involves interactions between a large number of proteins and indirect regulation by many others, it is likely that there are other miRNAs playing roles in the regulation of these cellular events. miR-221 and miR-222, for example, target the 3′ UTR of p27 Kip1 , a tumor suppressor gene that has been demonstrated to promote apoptosis [52] [53] [54] . Further study will certainly identify additional miRNAs critical to the ability of cancer cells to escape apoptosis.
miRNA regulation of 3p21.region tumor suppressor genes
More than 25 years have passed since the first identification and characterization of deletions in the short arm of chromosome 3 (3p) in small cell lung cancer cell lines and cultures [55] . More recent evidence demonstrates that loss of expression in the 3p region occurs in up to 90-100% of lung tumors and may play a critical role in the initiation of lung tumorigenesis [56] . Although the functions of the genes located in this region have not been fully elucidated, several act as tumor suppressors by causing the dysregulation of critical intracellular processes such as apoptosis [57, 58] . It has been proposed that hemizygous deletion of tumor suppressor genes in the 3p region could be coupled with other regulatory interactions that result in further down-regulation of gene expression, thereby inducing clonal outgrowth and tumor initiation [56] . Evidence is emerging that tumor suppressors in this region are likely to be regulated by miRNA activity. FUS1/TUSC2 is a tumor suppressor gene located on 3p21.3 that has been shown to be negatively regulated by the activities of miR-197, miR-93, miR-98, and miR-378 [9, 59] . Reduced or complete loss of Fus1 expression was found in 82% and 100% of non-small cell and small cell lung cancer cell lines [60] , and elevated levels of miR-93 and miR-197 have been shown to correlate with reduced Fus1 expression in NSCLC tumor specimens [59] . This and other evidence suggest that low Fus1 levels are the result of posttranscriptional miRNAmediated negative regulation [57, 61] which could be enhanced in a haploinsufficient Fus1 background. Although miRNA expression and function in the context of 3p21 deletions needs further investigation, evidence suggests that miRNA regulation of the remaining alleles of 3p21 tumor suppressor genes is important to the initiation and progression of lung cancer.
miRNA regulation of angiogenesis
The formation of new vasculature is crucial for tumor development. Solid tumors >1-2 mm 3 need to recruit new blood vessels to remove metabolic waste and provide oxygen and nutrients, a critical process that allows small developing neoplasias to enter a state of uncontrolled proliferation. Access to new vascularization also provides the tumor with new routes for dissemination, and current thought is that the degree of vascularization of a solid tumor is a direct indicator of its metastatic potential. Prior to the formation of neovasculature, a developing solid tumor is generally in an oxygen-starved or hypoxic state, triggering the release of a variety of angiogenic molecules and growth factors that recruit new blood vessels to the tumor site by promoting local basement membrane degradation, endothelial cell invasion, migration, and proliferation, resulting in the formation of capillary tubes [62, 63] . Pathways controlling these complex processes have been the focus of efforts to use novel therapeutics to inhibit this process and starve developing tumors of oxygen and nutrients. The vascular endothelial growth factor, for example (VEGF) is an important mediator of angiogenesis during tumor development, and this molecule and its receptor (VEGFR) have been primary targets of therapies designed to target pathological angiogenic signaling [64] .
Although their specific roles in lung cancer angiogenesis are poorly characterized to date, many of the previously described miRNAs have been found to be important regulators of angiogenesis in other contexts. Preliminary work by Yang et al. [65] showed that mice homozygous for a deletion in the miRNA processing gene Dicer were not viable and died within 14.5 days of gestation due to a lack of angiogenesis. Other studies have confirmed an important role for Dicer-mediated miRNA processing in the angiogenic response in vitro and in vivo both during normal physiological processes and in the context of cancer models [66] [67] [68] [69] [70] [71] . miR-126 is highly expressed during embryonic development and in endothelial cells [72] , implicating this miRNA in promoting angiogenic processes. In vivo evidence also shows that miR-126 is involved in the regulation of endothelial responses to angiogenic growth factors such as VEGF and that targeted deletion of this miRNA results in defective vascularization and embryonic death in both mice and zebrafish [72] [73] [74] . Liu et al. [75] investigated the involvement of miR-126 in the regulation of angiogenic processes in a lung cancer model. They found decreased expression of miR-126 and increased expression of VEGF-A in various lung cancer cell lines and showed that introduction of miR-126 using a lentiviral vector could down-regulate the expression of VEGF-A and inhibit growth. They also observed significant reductions in average tumor weight in mice inoculated with miR-126-infected tumor cells compared to control mice inoculated with tumor cells infected with control vector (p<0.001). Other miRNAs have been found to control angiogenic processes by directly regulating angiogenic factor production [76] . For example, several miRNAs have been predicted to target VEGF through both competitive (miR-93, miR-125a, miR-302d, miR-373, and miR-378) and coordinated (miR-15b, miR-16, miR-20a, and miR-20b) interactions, and transfection of miR-20a and miR-20b has been shown to regulate the expression of VEGF and other angiogenic factors in human carcinoma cells in vitro [77] .
Other factors involved in angiogenesis have been implicated as targets of miRNA regulation. These include the miR-17-92 cluster (miR-17, miR-18a, miR-19a, miR20a, miR-19b-1, and miR-92a-1) which down-regulates anti-angiogenic proteins such as thrombospondin-1 (Tsp1) and connective tissue growth factor [78] and has been shown to induce tumor vascularization when overexpressed in a mouse model of colon cancer. miRNAs that restrict angiogenesis by inhibiting endothelial cell migration and proliferation include miR-221 and miR-222, which target the stem cell factor receptor c-kit, a ligand involved in stem cell factor-mediated angiogenesis [79] . Several other miRNAs found to be positive regulators of angiogenesis have been identified in vitro, including miR-27b, miR130a, and let-7 [68, 80, 81] .
Identification of these miRNAs as important regulators of angiogenesis is providing a greater understanding of the complex pathways involved in tumor growth. Further work is needed to characterize their roles in regulating neoangiogenic processes in clinical settings, which should also provide more opportunities for therapeutic intervention through reducing the ability of cancer cells to modify their microenvironments to promote survival and proliferation.
miRNA regulation of metastasis and invasion
Invasion of a primary tumor into surrounding tissues followed by dissemination and growth of secondary malignancies (metastasis) requires a concerted series of events including dissociation of primary tumor cells from the primary neoplasia, entry into the circulatory system, and colonization at distant sites. Failure of any of these steps precludes metastasis, making the spread of cancer to distal sites a highly inefficient process. It has been estimated that fewer than 1 in 10,000 of disseminated cancer cells develop distant macroscopic malignancies [82] . Nevertheless, metastasis is a common event in cancer pathology and represents the primary cause of cancer-related mortality. The series of steps needed for metastatic spread involves changes in the expression of many genes; investigations of miRNA regulation of these steps have identified several miRNAs that either promote or inhibit metastatic potential.
A process central to the study of cancer metastasis is the epithelial to mesenchymal transition (EMT). Although extensive during embryonic development, this cellular event is rare in normal adult human cells, occurring predominantly during wound healing and kidney fibrosis [83, 84] . EMT is characterized by the loss of E-cadherinmediated cell adhesion and an increase in cell motility, and cancer cells often initiate this cellular event to promote invasion and metastasis. Conversion to the mesenchymal state is proposed to allow cancer cells to break free from the primary tumor, invade the basement membrane for entry into the circulation, and colonize to distant sites. EMT is also a reversible process, and cancer cells will revert back to a proliferative epithelial phenotype following colonization at a distant metastatic site [85] . The important role of miRNAs in positively regulating metastatic potential and the EMT was first highlighted by the discovery that the ectopic expression of miR-10b could promote tumor invasion and metastasis in normally non-aggressive breast cancer cells [86] . Forced expression of this miRNA in nonmetastatic xenografts using two different cell lines had no effect on the growth rates of these cells, but significantly increased invasive potential and the appearance of lung metastases. miR-10b inhibits the expression of HOXD10, a transcriptional repressor that acts to reduce the expression of a variety of factors involved in cell invasion and migration [87, 88] . miR-10b was also shown to be the most significantly up-regulated miRNA in glioblastoma multiforme compared to normal tissues by microarray analysis [89] and was also shown to be over-expressed in pancreatic adenocarcinoma, one of the most aggressive tumors with respect to early metastatic potential and poor survival [90] . Several other miRNAs have been found to positively regulate metastatic potential of cancer cells. For example, over-expression of miR-21 has been associated with both liver metastasis and high levels of expression of the proliferation marker Ki-67 in pancreatic tumors [91] . Transfection of a panel of miRNAs in a non-metastatic breast cancer cell line (MCF-7) revealed two miRNAs (miR-373 and miR-520c) that induced a migratory and invasive phenotype with no effect on cell proliferation in vitro, and tail vein injection of luciferase-tagged MCF-7 cells expressing either of the two miRNAs in SCID mice showed high levels of lung or osteolytic metastases compared to injection of control cells or cells expressing a mutant form of miR-373 [92] . These effects were explained by miRNA-mediated suppression of CD44, a cell surface glycoprotein involved in cell-cell interactions, cell adhesion, and migration [93] .
miRNAs are also involved in negatively regulating EMT and tumor metastasis. The miR-200 family of miRNAs has recently been identified as a potent regulator of EMT [94] . Members of this family have been shown to cooperatively regulate the E-cadherin transcriptional repressors ZEB1 and ZEB2 [94] [95] [96] [97] , with ectopic expression of miR-200 family members increasing E-cadherin expression and reducing the motility of cancer cells. Conversely, reducing miR-200 levels induced EMT in a cancer cell line that expressed high levels of these miRNAs [94] . In another study, invasive breast cancer cells with a mesenchymal phenotype or breast cancer specimens that lacked E-cadherin expression were notably devoid of miR-200 expression [95] Additional miRNAs have been identified as negative regulators of cellular metastatic potential. A recent study used microarray-based profiling to evaluate miRNA expression in breast cancer cells previously identified to have high metastatic potential [99] . Several miRNAs had highly reduced expression in metastatic sub-lines compared to the parental cells, and forced expression of three-miR-335, miR-206, and miR-126-using a retroviral-based expression system reduced the ability of otherwise metastaticprone cells to metastasize to lung or bone. Analysis of archived primary breast cancer tissue also showed that patients with low expression of miR-335, miR-206, or miR-126 had a shorter time to metastatic relapse. Low levels of miR-335 or miR-126 were associated with poor overall metastasis-free survival relative to patients whose tumors expressed high levels of these miRNAs. An investigation of miR-126 in the regulation of invasive potential in lung cancer revealed an inverse relationship between Crk and miR-126 expression in squamous cell tumors [100] . Forced over-expression of miR-126 reduced the expression of Crk protein, which is a mediator of signaling pathways important for a variety of cellular processes including motility and adhesion, and reduced expression of which leads to cancer cell invasion [101, 102] .
Overall, results from these studies highlight the importance of miRNAs in regulating invasive and metastatic processes and the potential utility of microRNA levels as a means of predicting therapeutic outcome. Although the roles of some of the miRNAs discussed above have not been investigated in lung cancers, the above studies indicate that these miRNAs target genes that are associated with general metastatic processes, suggesting that their involvement in lung tumor metastasis and invasion is worth investigating.
The multiple functional properties of miRNAs
Since miRNAs commonly have multiple target genes, a single miRNA can affect multiple cellular processes in tumorigenesis. As summarized in Table 1 , several miRNAs have been shown to target multiple cancer-related genes and processes. For example, in addition to targeting PTEN, miR-21 also targets PDCD4, a pro-apoptotic gene that inhibits tumorigenesis and whose down-regulation has been linked to poor survival in colon and lung cancer patients [103] [104] [105] , and the AP-1 transcription factor, a heterodimer made up of members of the c-Fos, c-Jun, ATF, and JDP families, which regulates a number of cellular processes including differentiation, proliferation, and apoptosis [106] . The let-7 family has been shown to inhibit the expression of several oncogenes including RAS, MYC, and HMGA2 [32] [33] [34] 107] . Interestingly, it has recently been observed that tumors with down-regulation of these miRNAs show a concomitant increase in miR-21 expression [108] . It is therefore suggested that the oncogenic miR-21 could be an indirect downstream target of the let-7 family. Several studies have implicated the miR-17-92 cluster of miRNAs as an actual oncogene with important regulatory effects on pathologic tumor cell proliferation in various tissues including breast and lung [109] [110] [111] . This cluster has been shown to inhibit lymphocytic PTEN expression leading to increased cancer cell proliferation in mice [112] . Members of this miRNA family also control the expression of the E2F family of transcription factors in an autoregulatory feedback loop [10, 113] . miR-15/16 targets G1 cyclins in an Rb-dependent manner [114] [115] [116] [117] , suggesting that this cluster could be involved in controlling different tumorigenic processes in various types of cancer. miR-29 downregulation of Mcl-1, coupled with the previously described role of miR-29 in epigenetic DNA methylation, means that enhanced expression could also affect more than one process during tumorigenesis [16, 45, 46] . Two other miRNAs, miR-221 and miR-222, target the 3′UTR of both Kit and the p27
Kip1 tumor suppressor [52] [53] [54] and are associated with resistance to TRAIL-induced apoptosis [118] . The miR-34 family has been demonstrated to target three genes that are involved in tumorigenesis: CDK4/6, cyclinE2, and E2F3 [49, 50] .
Overall, the above studies support multiple roles for individual miRNAs in regulating tumorigenic processes in a variety of tumors. These varied roles of a single miRNA highlight the overall complexity of miRNA-based regulation. In the context of miRNAs as therapeutic targets, the fact that one miRNA targets multiple genes could be beneficial if the multiple targets of an individual miRNA function in the same direction with respect to promoting cancer cell proliferation, which appears to be true in most cases. On the other hand, it could also create significant side effects if the multiple target genes function in opposite directions. The thorough dissection of the myriad interactions within and between miRNAs and their targets will therefore be required for the development of effective therapeutic approaches.
The dysregulation of miRNA expression in cancer development
Emerging evidence shows that deregulation of miRNAs might be a primary driver of cancer initiation and progression, meaning that a greater understanding of the regulatory mechanisms of miRNA expression could lead to novel strategies for the prevention and treatment of cancer. Several studies have investigated the mechanisms regulating the expression of miRNAs that play important roles in tumorigenesis. For example, as an anti-apoptotic miRNA, miR-21 has been shown to be up-regulated in various cancer types including lung cancers [119, 120] . Seike et al. [48] demonstrated that increased EGFR signaling due to a positive EGFR mutational status could enhance expression of miR-21, suggesting that miR-21 is a regulatory target of EGFR. Recent work has shown that miR-21 acts as both a target and regulator of the AP-1 transcription factor [106] , demonstrating a novel type of auto-regulatory loop that highlights the potential complexity of miRNA-mediated regulation of oncogenic processes involved in cancer cell proliferation. Another study investigated the expression of miR-10b, which is highly expressed in metastatic breast cancer cells and positively regulates cell migration and invasion, and showed that it is directly regulated by Twist, a transcription factor critically involved in EMT [86] .
The miR-34 family of miRNAs is under-expressed in a variety of tumors. miRNA profiling shows that the expression of miR-34a, miR-34b, and miR-34c are directly correlated with expression of the p53 tumor suppressor [51] , and these miRNAs are induced in a p53-dependent manner by oncogenic stress and DNA damage. Ectopic expression of miR-34a, miR-34b, and miR-34c induces cell cycle arrest in tumor cell lines [51] . These data suggest that the p53-dependent expression of miR-34 and the subsequent effects on the translation of downstream targets could be a primary mechanism by which p53 induces cell growth arrest and apoptosis. The miR-17-92 cluster of miRNAs is often over-expressed in lung cancer and B cell lymphomas and has been found to promote tumor cell proliferation in these tumors [109, 110] . Members of this miRNA family can be induced by c-Myc, and its expression is also regulated in an autoregulatory feedback [10, 113] .
The above data not only indicate that the deregulation of miRNAs may play a primary role in cancer development but also suggest that many well-studied cancer-related genes, such as EGFR and p53, control expression of oncogenic or tumor suppressor miRNAs. The interactions of these regulatory elements during tumorigenesis add another level of complexity to the process of cancer cell transformation, elucidation of which will be important for the future of the field.
Clinical applications of miRNAs in lung cancer diagnosis and therapy
MicroRNAs represent a novel paradigm in gene regulation and homeostatic control, and research continues to identify new roles for these regulatory elements in the development and progression of cancer. As these molecules are further characterized, new clinical applications will be developed that will provide oncologists with diagnostic and prognostic tools for stratifying patients based on risk and projected outcome. The identification of specific miRNA profiles could predict response to particular drugs or drug classes, and the variable presence of miRNAs during the course of treatment could also be used for monitoring therapeutic response and assessing the degree of residual disease. Further characterization of the highly complex miRNA regulatory networks will also lead to the identification of many new therapeutic targets and agents by which we may be able to repair the dysregulated processes that define the hallmarks of malignant growth.
Prognostic and diagnostic applications
The central involvement of miRNAs in the development and progression of cancer suggests that these regulatory elements could be particularly useful for extracting diagnostic and/or prognostic information. Current data indicate that every tumor type analyzed by miRNA profiling shows differential expression of miRNAs compared to normal tissues [121] and that particular miRNA signatures are associated with overall prognosis. An expression profile signature of nine miRNAs including miR-23a, miR23b, miR-24-2, miR-29c, miR-146, , miR-155, miR-181a, miR-221, and miR-222 was shown to correlate with time-todisease progression in patients with chronic lymphocytic leukemia (CLL) [45] , and the expression of miR-196a-2 and miR-21 have been significantly associated with survival in patients with pancreatic or colon cancer, respectively [90, 122] . A study in lung cancer showed that high mir-155 and low let-7a-2 expression correlated with poor survival [16] . An independent study of 143 resected lung tumors also showed significantly shorter survival in patients with reduced let-7 expression regardless of disease stage (p=0.0003) [123] . Several other miRNAs have also been shown to have possible diagnostic or prognostic value. These include protective (let-7, miR-221) and high-risk (miR-137, miR-372, and miR-182) miRNAs, which have been shown to predict the likelihood of survival in lung cancer patients [124] , and the miR-17-92 cluster, which is greatly increased in expression in lung cancer [109] .
Results from these studies suggest that most protective miRNAs are usually down-regulated in lung cancer while those associated with high risk are generally up-regulated [125] and that differential expression of miRNAs could have diagnostic significance and prognostic value.
miRNAs have also been shown to be predictive of response to cancer therapy. As previously described, miR128b was found to regulate EGFR in NSCLC cell lines, and loss of heterozygosity of miR-128b was shown to significantly correlate with response to EGFR-targeted therapy. Altered expression of let-7 was observed in response to radiotherapy, with forced over-expression of let-7 in lung cancer cells found to sensitize them to radiotherapy in vitro and to increase radiation-induced cell death in an in vivo Caenorhabditis elegans model [126] . Additional examples where miRNA status was found to predict response to therapy have emerged in other tumor types. For example, patients with hepatocellular carcinoma had better response to interferon-alpha therapy when the tumor expression level of miR-26 was low [127] . Further research into the complex regulatory networks modulated by miRNAs will identify additional miRNAs that predict response to existing therapies, providing clinicians with additional tools for stratifying patients and optimizing individualized therapy regimens.
The utility of circulating miRNAs for cancer diagnosis is also being investigated, highlighting their potential as noninvasive diagnostic tools for cancer detection. Plasma levels of both miR-92 and miR-17-3p were found to be significantly elevated in patients with colorectal cancer (CRC) compared to controls (p<0.0005), and these levels were significantly reduced in CRC patients following resection of the tumors (p<0.05) [128] . In another study, specific serum miRNA expression profiles have also been identified in patients with lung and colon cancers, and two of the miRNAs, miR-25 and miR-223, were further validated in an independent trial of 75 healthy donors and 152 NSCLC patients, suggesting that these two miRNAs have potential to serve as diagnostic marker for NSCLC [19] . Other miRNAs such as miR-141 and miR-21 have been reported to be predictive of the presence of prostate cancer or to act as a biomarker for the diagnosis of B cell lymphoma, respectively [18, 129] . The presence of solid malignancies is typically confirmed by biopsy, an approach that is ineffective for evaluating the existence or extent of metastatic spread. The development of noninvasive protocols for diagnosing tumors is therefore of substantial clinical interest, and the measurement of circulating miRNAs could be a promising approach for the timely detection and diagnosis of both primary and metastatic malignancies.
Variability in lung cancer histology and prognosis means that better methods are needed for classifying lung tumors and stratifying patients for traditional cytotoxic therapies. In addition, the advent of targeted therapies means that molecular classification of particular lung cancer subtypes can further direct the individualization of therapeutic modalities and improve patient outcomes. miRNAs have emerged as a potentially effective method for classifying specific tissues, and preliminary studies indicated that miRNA profiles could distinguish squamous and nonsquamous lung cancer histologies [16] . More recently, Lebanony et al. [130] found that expression of miR-205 was a highly specific biomarker for squamous cell lung carcinoma. Following microarray miRNA profiling and further characterization of miRNA expression levels, miR-205 was shown to distinguish squamous cell carcinoma from adenocarcinoma subtypes with a high degree of specificity (90%) and sensitivity (96%). From these data, the authors developed and validated a diagnostic protocol providing a potentially effective and convenient assay for classifying lung cancer histological subtypes. Other studies have also identified miRNA profiles that potentially distinguish between adenocarcinoma and squamous cell tumors [131] . These methods could prove to be invaluable by providing clinicians with additional tools to individualize therapy.
MicroRNAs also have potential for diagnosing the origin of metastases based on differential expression of these regulatory elements relative to normal tissue. Metastatic tumors of unknown origin account for up to 5% of cancers [132] ; these cases represent a substantial clinical dilemma due to the difficulty of early detection and the lack of data for appropriate clinical management. Systematic miRNA expression analysis has been shown to outperform messenger RNA profiling for distinguishing and diagnosing poorly differentiated tumors [133] , with several studies reporting that overall miRNA expression levels are lower in tumors than in normal tissue. miRNA expression may therefore be related to the degree of differentiation, a possibility that has been supported by other profiling studies. These data suggest that miRNAs could be an effective tool for identifying the presence and origin of small malignant growths against the background of normal physiological activity.
Mutational status of oncogenic miRNAs and regulatory regions in known oncogenes represents another strategy by which to identify high-risk patients. Germline mutations in miRNAs have been identified that confer a higher predisposition for developing cancer. MicroRNA mutations were identified in approximately 10% of patients with CLL [134] , and a germline G to A mutation in let-7e was recently found in a patient with prostate cancer that further investigation showed caused reduced expression of this miRNA in vivo [135] . Common genetic variations including single nucleotide polymorphisms in either miRNAs or miRNA complementary sites in the 3′UTRs of oncogenes have also been identified that can confer risk for developing malignancies in the lung, breast, or thyroid (reviewed in [134] ).
The above studies demonstrate that miRNA profiling has enormous diagnostic and prognostic potential, with several significant advantages over traditional approaches.
Targeting miRNAs for therapeutic benefit
microRNA regulation of multiple cancer-related pathways provides numerous opportunities for therapeutic intervention. Competitive inhibition of miRNAs or the delivery of exogenously produced miRNAs could provide substantial therapeutic benefit by reducing the activity of prooncogenic miRNAs or enriching cells with anti-oncogenic miRNAs, respectively. These approaches are still in the preclinical stages, although intriguing evidence is emerging that supports their use in clinical applications. Mimics of miRNAs including miR-15a, miR-16-1, and miR-29 have been introduced into mouse models, showing that these approaches can suppress the growth of leukemic cells [136] , and expression of miR-29 family members has been shown to reduce tumorigenic potential in a lung cancer model [39] . Exogenous delivery of a synthetic let-7 mimic has been used to mediate remission of established NSCLC tumors in mice [32] .
Unlike miRNA mimics, miRNA inhibitors are not processed by the miRNA biogenesis pathway. Such inhibitors are chemically modified single-stranded oligonucleotides complementary to mature miRNAs. The chemical modifications, including phosphorothioate, 2′-O-methyl, and locked nucleic acid (LNA) substitutions increase their resistance to degradation by nucleases. The inhibitors are designed to bind to the mature miRNA within the RISC complex and act as competitive inhibitors, but can also bind pri-miRNA or pre-miRNA and abrogate their processing, export from the nucleus or incorporation into the RISC complex. Treatment with a miRNA inhibitor (antagomir) [137] of oncogenic miR-17-5p resulted in complete tumor regression in 30% of mice [138] . Results from other studies in mice and primates showed effective silencing of miR-122 using inhibitors with LNA substitutions and cholesterol conjugation with no evidence of treatment-related toxicity [139] , supporting the development of these approaches in the clinical setting.
Overall, miRNA-based therapeutics have enormous, but as yet, unrealized potential. Adeno-associated virus-mediated delivery of miR-26a has been used to down-regulate cyclins D2 and E2 and thereby ameliorate hepatocellular carcinoma in mice [140] , suggesting an alternative to delivery of either single-or double-stranded miRNA mimics. Future work will focus on both chemical modifications and delivery vehicles in order to maximize the therapeutic benefits and minimize the side effects of strategies designed to alter intracellular levels of specific miRNAs.
Conclusions
The study of microRNAs has evolved rapidly since the discovery of this important class of regulatory molecules. In the field of cancer biology, researchers have found many examples of differential miRNA regulation between normal and cancer cells, identifying miRNA signatures that are clearly associated with disease risk, diagnosis, prognosis, and therapeutic response. Studies are also illuminating the connections between miRNAs and the initiation and progression of malignant neoplasias and the basic biological roles that they play in tumor cell survival, invasion, metastasis, and angiogenesis. Many issues still need to be addressed, however, before miRNAs can be effectively integrated into the field of clinical oncology. For example, further evaluation of miRNAs as noninvasive serum markers is required before they can improve upon current methods for cancer diagnosis. More preclinical and clinical studies are needed to evaluate miRNA mimics or inhibitors for arresting tumor growth, as are further studies assessing techniques for improving the pharmacokinetics, specificity of delivery, and minimization of toxicity of these molecules for enhanced therapeutic benefit. miRNA dysregulation in particular tumor subtypes need to be further investigated, which may aid the development of newer therapies that specifically target tumor cells with particular molecular and regulatory profiles. Overall, miRNAs are ubiquitous regulatory molecules that hold great promise for increasing our understanding of cancer and for improving upon current diagnostic and therapeutic methods. Further evaluation of their value in cancer diagnostics and of the functional consequences of their manipulation will provide researchers and oncologists with a wealth of new tools to characterize and treat this prevalent and diverse disease.
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